TRDA · Entrada Therapeutics, Inc. · Debt
$5.17
-0.27 (-4.96%)
At close · Nov 12
Return incl. dividend (before tax)
Play latest call
Q1 2026 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of our recurring losses from operations and recurring negative cash flows from operations, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$202.41M
Shares
39.15M
Volume · Nov 12
808.67K
Avg daily vol (3M)
365.68K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Completed filing coverage through Mar 22, 2022Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-09-30 | USD 4,621,000 | 10-Q filed 2026-11-05 |
| Noncurrent operating lease liabilities | 2026-09-30 | USD 42,692,000 | 10-Q filed 2026-11-05 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1689375
CUSIP
29384C108
13F (30d)
70 filings
57 filers
Visit website
Investor relations